[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353158-105":59,"doc-detail-353158-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","assessing-contribution-of-effect-in-oncology-combination-therapies-lessons-learned-to-inform-and-optimize-future-registrational-trial-designs","Assessing contribution of effect in oncology combination therapies - lessons learned to inform and optimize future registrational trial designs","","Combination therapies can substantially improve outcomes for patients with cancer, yet they create difficulties when attributing the contribution of effect (COE) to each component. Factorial trials are rigorous for establishing COE but are frequently impractical for rare cancers, aggressive disease, evolving standards of care, or monotherapy elements with limited activity. Alternative registrational trial designs are required to balance rigor, feasibility, and patient acceptability.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/assessing-contribution-of-effect-in-oncology-combination-therapies-lessons-learned-to-inform-and-optimize-future-registrational-trial-designs/353158/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/assessing-contribution-of-effect-in-oncology-combination-therapies-lessons-learned-to-inform-and-optimize-future-registrational-trial-designs/353158.png","ImageObject",300,407,{"name":92,"@type":93},"Kurz","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-16","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",18,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is determining contribution of effect (COE) challenging in oncology combination therapies?","Question",{"text":113,"@type":114},"Factorial trials are the most rigorous method, but they are often impractical due to rare cancers, aggressive disease, evolving standards of care, or monotherapy components with limited activity. This makes it hard to attribute meaningful benefit to each component.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What does the article say about alternative approaches to registrational trial designs?",{"text":118,"@type":114},"Alternative designs can support COE assessment when grounded in prior evidence and mechanistic understanding. The article emphasizes balancing scientific rigor with feasibility and patient acceptability.",{"name":120,"@type":111,"acceptedAnswer":121},"Which categories of evidence can be used to design combination trials without factorial arms?",{"text":122,"@type":114},"The article identifies four categories: data from the same combination in other tumor types, data from agents with similar mechanisms, data from early-phase or parallel combination trials in the same disease setting, and strong mechanistic/clinical evidence showing a monotherapy lacks activity and/or causes harm.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},353158,1790623256,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":14,"preview_urls":147},2336478945635,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","The Oncologist, 2026, 31, oyag222  \n[https://doi.org/10.1093/oncolo/oyag222](https://doi.org/10.1093/oncolo/oyag222)  \n[Published: June 3](Published: June 3), 2026  \nCommentary  \nAssessing contribution of effect in oncology combination therapies: lessons learned to inform and optimize future registrational trial designs  \nHillary S. Andrews, PhD*, 1, , Raja Agnihotram, MS2, Gideon Blumenthal, MD3, Julie Bullock, PharmD4, Grace Collins, MS1, Gary J. Doherty, PhD5, Anna F. Farago, MD, PhD6, Yuko Ishii, PhD7,  \nSreeneeranj Kasichayanula, PhD8, Michael LeBlanc, PhD9, Elena Levi-D’Ancona, PhD1, Chunze Li, PhD10, Karen McCullough, PhD4, Phuong Khanh (PK) Morrow, MD11, Bernat Navarro, PhD1,  \nPunam Sandhu, PhD12, Sujay Shah, MD2, Elad Sharon, MD13, Zhen Su, MD14, Carol Vallett, EdD7, Yolanda Villalobos, MBA15, Jeff D. Allen, PhD1, Mark D. Stewart, PhD1  \n1 Friends of Cancer Research, Washington, DC, 20036, United States 2Johnson and Johnson Innovative Medicines, Raritan, NJ, 08869, United States 3 Pfizer, Inc, New York, NY, 10001, United States  \n4GSK, Philadelphia , PA, 19112, United States 5AstraZeneca, Cambridge, United Kingdom 6Amgen, Inc, Thousand Oaks, CA, 91320, United States  \n7 Independent Patient Advocate, Washington, DC, 20036, United States  \n8Gilead Sciences., Inc, Forester City, CA, 94404, United States 9 Fred Hutchinson Cancer Center, Seattle, WA, 98109, United States 10Genentech, Inc, San Francisco, CA, 94080, United States 11Takeda Pharmaceuticals, Inc, Cambridge, MA, 02142, United States 12 Daiichi Sankyo, Basking Ridge, NJ, 07920, United States 13 Dana-Farber Cancer Institute, Boston, MA, 02215, United States 14 Marengo Therapeutics, Cambridge, MA, 02139, United States 15 Eli Lilly and Company, Indianapolis, IN, 46285, United States  \n*Corresponding author: Hillary S. Andrews, PhD, Friends of Cancer Research, 1800 M Street NW Suite 1050S, Washington, DC 20036, USA ([handrews@focr.org](handrews@focr.org)) .  \nAbstract  \nCombination therapies can be used to significantly improve clinical outcomes in patients undergoing treatment for cancer; however, they also present challenges when establishing the contribution of effect (COE) for each component. Although factorial trials remain the most rigorous approach for determining COE, they are often impractical, such as in settings with rare cancers, aggressive disease, evolving standards of care, or monotherapy components with limited activity. As more combination regimens are co-developed from the outset, alternative approaches to registrational trial designs are needed to balance scientific rigor with feasibility and patient acceptability. Thoughtfully designed alternative approaches can support an understanding of COE when grounded in prior evidence and mechanistic understanding. Four major categories of evidence emerge to support designing combination trials without factorial arms: (1) data from trials of the same combination in other tumor types; (2) data from trials of agents with similar mechanisms of action; (3) data from early-phase or parallel trials of the combination within the same disease setting; and (4) strong mechanistic or clinical evidence that a monotherapy component lacks activity and/or imposes harm, supporting omission of inactive arms. Early regulatory engagement, prespecified decision rules, and transparent justification of design choices are essential to ensure that combination regimens provide meaningful improvement in efficacy over monotherapies while minimizing unnecessary toxicity. Applying these principles to combination therapy development can maximize patient benefit while maintaining scientific rigor.  \nKey words: combinations; clinical trial design; factorial design; totality of evidence  \nReceived: January 13, 2026. Accepted: May 29, 2026 © The Author(s) 2026. Published by Oxford University Press.  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License ([https://creativecommon","cbCaiaQFHQTWGjRD","https://ap.wps.com/l/cbCaiaQFHQTWGjRD","pdf",783709,11,"English","# Abstract\n## Contribution of effect (COE) in combination therapies\n## Why factorial trials may be impractical\n## Alternative registrational trial design approaches\n## Evidence categories and regulatory considerations\n# Introduction\n## Challenges in demonstrating meaningful component COE\n## Ideal vs unfavorable combination efficacy patterns\n## FDA guidance and methodological approaches","[{\"question\":\"Why is determining contribution of effect (COE) challenging in oncology combination therapies?\",\"answer\":\"Factorial trials are the most rigorous method, but they are often impractical due to rare cancers, aggressive disease, evolving standards of care, or monotherapy components with limited activity. This makes it hard to attribute meaningful benefit to each component.\"},{\"question\":\"What does the article say about alternative approaches to registrational trial designs?\",\"answer\":\"Alternative designs can support COE assessment when grounded in prior evidence and mechanistic understanding. The article emphasizes balancing scientific rigor with feasibility and patient acceptability.\"},{\"question\":\"Which categories of evidence can be used to design combination trials without factorial arms?\",\"answer\":\"The article identifies four categories: data from the same combination in other tumor types, data from agents with similar mechanisms, data from early-phase or parallel combination trials in the same disease setting, and strong mechanistic/clinical evidence showing a monotherapy lacks activity and/or causes harm.\"}]","Assessing contribution of effect in oncology combination therapies - lessons learned to inform and optimize future registrational trial designs | PDF",1790103340,28,[148,152],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/e967d39903db92d95a7e8db856abee4e.webp",983,1291,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/ba33de1ca0661015513dc1948d0b5493.webp",982,1290]